Evidence map›Paper›PMID 33849461›Full record

ArticleBMC infectious diseases2021

European data sources for computing burden of (potential) vaccine-preventable diseases in ageing adults.

Estelle Méroc, Janeri Fröberg, Timea Almasi, Brita Askeland Winje, Alejandro Orrico-Sánchez, Anneke Steens, Scott A McDonald, Kaatje Bollaerts, Mirjam J Knol

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 4 countries.

Estelle MérocP95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium. estelle.meroc@p-95.com.
Janeri FröbergRadboud University Medical Center, Radboud Institute for Molecular Life Sciences, Laboratory of Medical Immunology, Section Paediatric Infectious Diseases, Geert Grooteplein 21, 6525 EZ, Nijmegen, the Netherlands.
Timea AlmasiSyreon Research Institute, Mexikoi str. 65/A, Budapest, 1142, Hungary.
Brita Askeland WinjeDepartment of Infection Control and Vaccine, Norwegian Institute of Public Health, PO Box 222, Skøyen, 0213, Oslo, Norway.
Alejandro Orrico-SánchezVaccines Research Unit, FISABIO (the Valencia Foundation for the Promotion of Health and Biomedical Research), Av. Catalunya, 21, 46020, Valencia, Spain.
Anneke SteensDepartment of Infection Control and Vaccine, Norwegian Institute of Public Health, PO Box 222, Skøyen, 0213, Oslo, Norway.
Scott A McDonaldCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, the Netherlands.
Kaatje BollaertsP95 Epidemiology and Pharmacovigilance, Koning Leopold III laan 1, 3001, Leuven, Belgium.
Mirjam J KnolCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720 BA, Bilthoven, the Netherlands.
KU Leuven · BENational Institute for Public Health and the Environment · NLNorwegian Institute of Public Health · NOFundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana · ESRadboud University Medical Center · NLSyreon Research Institute (Hungary)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo guide decision-making on immunisation programmes for ageing adults in Europe, one of the aims of the Vaccines and InfecTious diseases in the Ageing popuLation (IMI2-VITAL) project is to assess the burden of disease (BoD) of (potentially) vaccine-preventable diseases ((P)VPD). We aimed to identify the available data sources to calculate the BoD of (P)VPD in participating VITAL countries and to pinpoint data gaps. Based on epidemiological criteria and vaccine availability, we prioritized (P) VPD caused by Extra-intestinal pathogenic Escherichia coli (ExPEC), norovirus, respiratory syncytial virus, Staphylococcus aureus, and pneumococcal pneumonia.

methodsWe conducted a survey on available data (e.g. incidence, mortality, disability-adjusted life years (DALY), quality-adjusted life years (QALY), sequelae, antimicrobial resistance (AMR), etc.) among national experts from European countries, and carried out five pathogen-specific literature reviews by searching MEDLINE for peer-reviewed publications published between 2009 and 2019.

resultsMorbidity and mortality data were generally available for all five diseases, while summary BoD estimates were mostly lacking. Available data were not always stratified by age and risk group, which is especially important when calculating BoD for ageing adults. AMR data were available in several countries for S. aureus and ExPEC.

conclusionThis study provides an exhaustive overview of the available data sources and data gaps for the estimation of BoD of five (P) VPD in ageing adults in the EU/EAA, which is useful to guide pathogen-specific BoD studies and contribute to calculation of (P)VPDs BoD.

Indexed as

Cost of IllnessAgingCaliciviridae InfectionsEuropeHumansIncidencePneumonia, PneumococcalQuality-Adjusted Life YearsRespiratory Syncytial Virus InfectionsSurveys and QuestionnairesVaccine-Preventable DiseasesBurden of diseaseElderlyInfectious diseasePublic healthVaccine

Identifiers

PMID33849461
PMCPMC8042717
OpenAlexW3155139919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.